According to investor Sarat Sethi, the time has come for investors to get back into British pharmaceutical company GSK. Sethi told the panel on CNBC’s “Halftime Report” on Monday that he has been adding to the stock that used to be known as GlaxoSmithKline since buying it a few months ago. Douglas C. Lane & Associates portfolio manager said, “Glaxo’s vaccine pipeline is huge. And in fact, it was completely zeroed out during Covid, because everyone was just focused on getting the right Covid vaccine.” was concentrating.” “So, at this point, you look at the stock, trades at 10 times earnings, it’s got a 4% dividend yield, they split [oral health company] Halon, it’s a pure play in the pharma conglomerate, and it’s long overdue,” he said. GSK shares have notably underperformed this year. While the S&P 500 has gained 7% since the start of 2023, Shares of GSK are up just 0.6% for the year. They underperformed the broader market index last year as well, falling more than 21% in 2022.” took a more negative view on care, saying she is undermining the sector after its outperformance last year. “There are some amazing companies,” Link said. “I think you have to be more selective this year, because I think a lot of — these stocks have gone a long way and they’ve done really remarkably well. And I think you can look at some of the other sectors are going to repatriate in the U.S. This is a place where you would step in and buy it. Why? Because your risk is defined and it’s very low risk.” However, Terranova clarified that he himself liquidated his position in the stock in October.